Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

332 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    CNIPA Decides First Batch Of Administrative Adjudications Of Significant Patent Infringement Disputes

    The amended Patent Law came into effect on June 1, 2021, in which the new added Article 70, paragraph 1 endows the CNIPA with the authority to solve patent infringement disputes which have a significant impact nationwide ...
    ChinaIntellectual Property
    Lung Tin
    Lung Tin
  • Article

    药品采购GPO:反垄断法警告你不能胡来

    我国的药品流通市场长期以来处于市场竞争和行政管制并存的状态。政府在引导药品价格形成市场机制的同时,也在积极探索通过行政干预缓#
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
Article

Set Up Steps For Biotech Businesses In China

China has witnessed a biotech boom over the past decade. Where previously the market was dominated by generics of variable quality and an opaque and highly bureaucratic regulatory system, recent government reforms, ...
ChinaFood, Drugs, Healthcare, Life Sciences
The Sovereign Group
The Sovereign Group
  • Article

    Circular On The Work Relating To The Implementation Of GB 9706.1-2020 And Supporting Concurrent Standards And Special Standards

    The National Medical Products Administration ("NMPA") issued the Circular on the Work Relating to the Implementation of GB 9706.1-2020 and Supporting Concurrent Standards and Special Standards
    ChinaFood, Drugs, Healthcare, Life Sciences
    CMS
    CMS
  • Article

    News & Cases from China: March 2023

    On 10 March, the National People's Congress approved the Institutional Reform Plan (Plan) that had been introduced by the State Council on 7 March. The Plan provided that, in order to accelerate...
    ChinaIntellectual Property
    Rouse
    Rouse
  • Article

    Highlights On China's Comprehensive Regulatory Reform Of Drugs And Medical Devices

    China has been endeavoring to make comprehensive and fundamental regulatory reform of drug and medical device, in particular in the drug and medical device registration system.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Jincheng Tongda & Neal
    Jincheng Tongda & Neal
  • Article

    Key Takeaways | Leveraging China’s biotech ecosystem

    A Paris roundtable examined China's transformation into a biotechnology powerhouse and the strategic opportunities this creates for European life sciences companies and investors. Industry leaders discussed how to structure cross-border partnerships that leverage Chinese innovation and development speed while navigating intellectual property protection, regulatory frameworks, and evolving geopolitical considerations.
    ChinaFood, Drugs, Healthcare, Life Sciences
    McDermott Will & Schulte
    McDermott Will & Schulte
  • Article

    疫情下药品进口法律法规简析

    疫情下药品进口法律法规简析
    ChinaFood, Drugs, Healthcare, Life Sciences
    DeHeng Law Offices
    DeHeng Law Offices
  • Article

    A Stratification Too Far? How The CNIPA Draws The Line On Patient Subgroups In A Recent Precision Medicine Invalidation Case

    A recent CNIPA invalidation case examines how precision medicine patents are evaluated in China, specifically addressing whether patient stratification based on biomarkers like serum alkaline phosphatase levels constitutes valid claim limitations. The decision provides critical guidance on what evidence is required to establish new patient subgroups and how disease markers must demonstrate clinical guidance value to support inventive step arguments.
    ChinaIntellectual Property
    Eagle IP
    Eagle IP
  • Article

    創新医療機器特別審査手順を背景にした特許出願戦略

    創新医療機器特別審査制度の紹介 過日、医療機器の研究開発およびイノベーションを促進し、医療機器の新技術の普及および応用を推し๫
    ChinaIntellectual Property
    Kangxin
    Kangxin
  • Article

    Brief Discussion About The Novelty Judgment Of Patent For Chiral Compounds Starting From "Contergan Event"

    The opportunity to decide writing this article is a startling photo that pop into my eyes when searching the meaning of the word "thalidomide" on the Internet.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Kangxin
    Kangxin
  • Article

    China’s Pharma Innovators Pursue A Range Of Deal Structures To Support Global Expansion

    China has emerged as a global pharmaceutical innovation powerhouse, leveraging its scientific expertise, AI capabilities, and streamlined regulatory environment to accelerate drug development.
    ChinaFood, Drugs, Healthcare, Life Sciences
    A&O Shearman
    A&O Shearman
  • Article

    Insights Into China Biotech's New Approach: Spin-Off-NewCo Model

    China's pharmaceutical industry is witnessing a notable surge in "pipeline spin-off projects", a model commonly referred to as the "Spin-off-NewCo" or "SON"...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    New Developments In China's Drug Change Management Regulations

    The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) recently released the Acceptance Review Guideline on Biological Products Changes (for Trial Implementation).
    ChinaFood, Drugs, Healthcare, Life Sciences
    Arnold & Porter
    Arnold & Porter
  • Article

    Several Issues In Foreign Investor’s Acquisition Of Pharmaceutical Enterprises

    People are growing increasingly conscientious about their health, and the pharmaceutical industry has become an important part of the national economy.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Broad & Bright
    Broad & Bright
  • Article

    China Compliance Update: Life Sciences — Summer 2026

    China's regulators intensified anti-corruption enforcement in the life sciences sector during the first half of 2026, introducing stricter oversight of medical data security, sales representatives, and public procurement processes. New administrative measures and judicial interpretations have lowered thresholds for criminal liability while expanding corporate accountability for employee misconduct.
    ChinaGovernment, Public Sector
    Arnold & Porter
    Arnold & Porter
  • Article

    China’s Rise As A Global Biopharma Innovation Hub: Navigating Trends, Opportunities, And Evolving Deal Structures

    China has rapidly emerged as a dominant force in early-stage biotech innovation, challenging traditional U.S. hubs like San Francisco and Boston through faster development timelines, lower clinical trial costs, and aggressive government support. As deal volume between Western biopharma companies and Chinese biotechs surges dramatically, industry leaders must navigate the complex balance between accessing China's growing scientific contributions and managing heightened geopolitical tensions and U.S. regulato
    GlobalFood, Drugs, Healthcare, Life Sciences
    WilmerHale
    WilmerHale
  • Article

    A Stratification Too Far? How The CNIPA Draws The Line On Patient Subgroups In A Recent Precision Medicine Invalidation Case

    Precision medicine is rapidly transforming the global healthcare landscape, providing more effective therapies and better patient outcomes through targeted solutions.
    ChinaIntellectual Property
    Eagle IP
    Eagle IP
  • Article

    Han Kun • Opinion | Brief Review Of The Measures For The Review Of Science And Technology Ethics (Trial) (Draft For Comments)

    On April 4, 2023, the Ministry of Science and Technology released the "Measures for Science and Technology Ethics Review (Trial) (Draft for Comments)" ("Draft for Comments")...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    Patent Issues For Life Science Companies In China

    Scientific discoveries are not patentable. Naturally existing materials without involvement of any technical treatment belong to scientific discoveries.
    ChinaIntellectual Property
    Liu Shen & Associates
    Liu Shen & Associates
  • Showing 201–220 of 332 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics